Recombinant Coagulation Factor Concentrate Market

Coagulation factor is the main drug for the treatment of hemophilia, and it has experienced the evolution and development from the first generation blood-derived coagulation factor products to the second generation recombinant products and the third generation long-acting recombinant products. Recombinant coagulation factors avoid the possibility of human infection and get rid of the dependence on plasma; long-acting products improve patient compliance and treatment convenience by prolonging the half-life of drugs, and long-acting recombinant coagulation factors are the trend of future research and development.

Recombinant Coagulation Factor Concentrate Market contains market size and forecasts of Recombinant Coagulation Factor Concentrate in global, including the following market information:

Global Recombinant Coagulation Factor Concentrate Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Recombinant Coagulation Factor Concentrate Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Recombinant Coagulation Factor Concentrate companies in 2021 (%)

The global Recombinant Coagulation Factor Concentrate market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

250 IU Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Recombinant Coagulation Factor Concentrate include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL and Baxalta, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Recombinant Coagulation Factor Concentrate manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Recombinant Coagulation Factor Concentrate Market, by Dose, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Recombinant Coagulation Factor Concentrate Market Segment Percentages, by Dose, 2021 (%)

250 IU

500 IU

1000 IU

2000 IU

Global Recombinant Coagulation Factor Concentrate Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Recombinant Coagulation Factor Concentrate Market Segment Percentages, by Application, 2021 (%)

Hopistial

Clinic

Others

Global Recombinant Coagulation Factor Concentrate Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Recombinant Coagulation Factor Concentrate Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Recombinant Coagulation Factor Concentrate revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Recombinant Coagulation Factor Concentrate revenues share in global market, 2021 (%)

Key companies Recombinant Coagulation Factor Concentrate sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Recombinant Coagulation Factor Concentrate sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bayer

Alprolix

Benefix

Idelvion

Lxinity

Rebinyn

Rixubis

CSL

Baxalta

Sanofi

Biogen

Pfizer

Novo Disk

Baxter

Wyeth

??????????????

????

????

????

???????????????